

January 07, 2020

## **Venturis Therapeutics - A positive new chapter in the life of the Company**

---

Dallas, TX January 7th, 2020 – Venturis Therapeutics, Inc. (“VT” or the “Company”) today announced that effective today January 7th, 2020, Cardiovascular Biotherapeutics, Inc. has changed its name to Venturis Therapeutics, Inc. “Since 2014, the Company has been transformed in many positive ways and we feel we have now reached the appropriate stage for the name change. This represents another and positive new chapter in the life of the Company. We believe that 2020 is shaping up to be a banner year for our Company and this is another step in the process,” VT’s Chairman and CEO, Calvin Wallen III, stated.

### **ABOUT VENTURIS THERAPEUTICS**

Venturis Therapeutics, Inc. is a biopharmaceutical company developing protein drug candidates to address diseases such as diabetic wounds, severe coronary heart disease, peripheral artery disease, erectile dysfunction, stroke, and spinal disk disease. The active pharmaceutical ingredient (“API”) in our drug candidates is FGF-1, a human protein that stimulates the growth of new blood vessels, thereby increasing the blood supply to ischemic organs and tissues.

### **FORWARD LOOKING STATEMENTS**

This news release contains forward-looking statements that involve risks and uncertainties. Actual results and outcomes may differ materially from those discussed or anticipated. For example, statements regarding expectations for new research, progress with clinical trials or future business initiatives are forward looking statements. Factors that might affect actual outcomes include, but are not limited to, FDA approval of VT drug candidates, market acceptance of VT products by customers, new developments in the industry, future revenues, future expenses, future margins, cash usage, and financial performance. Additionally, until VT is cash flow positive from operations, the Company is dependent upon raising capital to fund its operations and meet its obligations as they come due. There can be no assurance that VT will be able to raise the necessary capital when needed.

SOURCE: Venturis Therapeutics, Inc.

---